111 results on '"Faedi, Marina"'
Search Results
2. Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life
3. Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial
4. Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
5. Correction to: Efficacy of initial temozolomide for high‑risk low grade gliomas in a phase II AINO (Italian Association for Neuro‑Oncology) study: a post‑hoc analysis within molecular subgroups of WHO 2016
6. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma
7. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study
8. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
9. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology)
10. Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study
11. Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer
12. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors
13. ACTR-20. EFFICACY OF INITIAL TEMOZOLOMIDE FOR HIGH-RISK LOW GRADE GLIOMAS IN A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY: A POST-HOC ANALYSIS WITHIN MOLECULAR SUBGROUPS OF WHO 2016
14. Erratum to 'Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life' [Eur J Cancer (2016) 69 (110–118)] (S095980491632487X)(10.1016/j.ejca.2016.10.004)
15. Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study (Journal of Neuro-Oncology, (2016), 128, 1, (157-162), 10.1007/s11060-016-2093-1)
16. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
17. ACTR-54. PATTERN OF RECURRENCE AND IMPACT ON SURVIVAL OF SALVAGE THERAPIES IN LOW-GRADE GLIOMAS FOLLOWING DOSE-DENSE TEMOZOLOMIDE
18. Erratum to: Benefit from anthracyclines in relation to biological profiles in early breast cancer
19. Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).
20. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
21. REGOMA: A Randomized, Multicenter, Controlled Open-Label Phase II Clinical Trial of Regorafenib Compared to Lomustine in Relapsed Glioblastoma Patients
22. ACTR-06. DOSE DENSE TEMOZOLOMIDE (TMZ) AS INITIAL TREATMENT FOR HIGH-RISK OLIGODENDROGLIAL TUMORS: LONG-TERM RESULTS OF A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY
23. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study
24. REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).
25. A phase II trial of temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: An AINO (Italian Association for Neuro-Oncology) study.
26. Bone health management in early breast cancer patients: An Italian osteoncology center experience.
27. Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer 69 (2016) 110–118]
28. Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life
29. Multiple Primary Tumors in a Family with Li-Fraumeni Syndrome with a TP53 Germline Mutation Identified by Next-Generation Sequencing
30. Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial
31. Does the duration of adjuvant temozolomide impact survival in glioblastoma patients? A retrospective analysis from an Italian registry (GLIOSTRY).
32. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
33. Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study
34. EPID-27GLIOSTRY (GLIOBLASTOMA REGISTRY) OF THE AINO (ITALIAN ASSOCIATION OF NEURO-ONCOLOGY): ANALYSIS OF FACTORS INFLUENCING SURVIVAL IN GLIOBLASTOMA PATIENTS RECEIVING THE NITROSOUREA FOTEMUSTINE AT FIRST PROGRESSION FOLLOWING THE STUPP REGIMEN
35. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma
36. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer
37. Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
38. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity.
39. GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.
40. Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study
41. Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer 69 (2016) 110–118]
42. Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?
43. Association of high volume center with survival for glioblastoma patients: Results from a prospective population-based registry (PERNO).
44. Analysis of long-term survival in patients with glioblastoma treated in the wide area of romagna (AVR).
45. Final results from a large prospective Italian population study on glioblastoma and correlations with MGMT status: The Project of Emilia-Romagna Region in Neuro-oncology (PERNO).
46. Analysis of long-term survival in patients with glioblastoma.
47. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
48. Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study.
49. LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation
50. Trastuzumab-induced cardiotoxicity in early breast cancer: Evaluation of possible risk and protective factors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.